Revelation in the neuroprotective functions of rasagiline and selegiline: The induction of distinct genes by different mechanisms

Expert Review of Neurotherapeutics

Volumn 13, Issue 6, 2013, Pages 671-684

  Naoi, Makoto ^a   Maruyama, Wakako ^b   Inaba Hasegawa, Keiko ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

apoptosis; Bcl 2; BDNF; GDNF; neuroprotection; Parkinson's disease; programmed cell death; rasagiline; selegiline; type A and B monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ARTEMIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOCHONDRIAL CREATINE KINASE; NERVE GROWTH FACTOR; NEUROTROPHIN; NEURTURIN; PERSEPHIN; PROTEIN BCL 2; PYRIDINE NUCLEOTIDE; RASAGILINE; SELEGILINE;

APOPTOSIS; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE INDUCTION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION SWELLING; NEUROPROTECTION; NONHUMAN; REVIEW;

ANIMALS; APOPTOSIS; GENE EXPRESSION; GENES, BCL-2; HUMANS; INDANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE;

EID: 84879094341     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.60     Document Type: Review

References (193)

1. Forno LS. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55(3), 259-272 (1996). (Pubitemid 26085575)
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39(6), 889-909 (2003). (Pubitemid 37130207)
3. Thomas B, Beal MF. Parkinson's disease. Hum. Mol. Genet. 16 Spec No. 2, R183-R194 (2007).
4. Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum. Mol. Genet. 19(R1), R21-R27 (2010).
5. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat. Med. 10(Suppl.), S2-S9 (2004). (Pubitemid 38901861)
6. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 66(10 Suppl. 4), S24-S36 (2006).
7. Mosley RL, Benner EJ, Kadiu I et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res. 6(5), 261-281 (2006). (Pubitemid 44849177)
8. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145(4), 1233-1248 (2007). (Pubitemid 46602738)
9. Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14(4), 478-500 (2009).
10. Riederer PF. Views on neurodegeneration as a basis for neuroprotective strategies. Med. Sci. Monit. 10, RA287-RA290 (2004). (Pubitemid 40268568)
11. Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat. Embryol. 181(3), 195-213 (1990). (Pubitemid 20153523)
12. Alves da Costa C, Checler F. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell. Signal. 23(6), 963-968 (2011).
13. Mochizuki H, Nishi K, Mizuno Y. Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture. Neurodegeneration 2, 1-7 (1993).
14. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131(Pt 8), 1969-1978 (2008).
15. Mizuno Y, Mochizuki H, Sugita Y, Goto K. Apoptosis in neurodegenerative disorders. Intern. Med. 37(2), 192-193 (1998).
16. Jellinger KA. Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med. 5(1), 1-17 (2001). (Pubitemid 33772981)
17. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53(Suppl. 3), S61-S70; discussion S70 (2003).
18. Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132(Pt 7), 1795-1809 (2009).
19. Anglade P, Vyas S, Javoy-Agid F et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12(1), 25-31 (1997). (Pubitemid 27106916)
20. Reed JC. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1(2), 111-121 (2002). (Pubitemid 41646518)
21. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4(5), 365-375 (2003). (Pubitemid 37280175)
22. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol. Rev. 57(2), 187-215 (2005). (Pubitemid 41043884)
23. Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5(10), 845-854 (2006). (Pubitemid 44480538)
24. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311(5985), 467-469 (1984). (Pubitemid 14035453)
25. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9(4), 703-707 (1998). (Pubitemid 28131289)
26. Riederer P, Lachenmayer L. Selegiline's neuroprotective capacity revisited. J. Neural Transm. 110(11), 1273-1278 (2003). (Pubitemid 37500748)
27. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szoko E. Pharmacological aspects of deprenyl. Curr. Med. Chem. 11(15), 2017-2031 (2004).
28. Ebadi M, Brown-Borg H, Ren J et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug Targets 7(11), 1513-1529 (2006). (Pubitemid 44718309)
29. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7(4), 295-309 (2006).
30. Naoi M, Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des. 16(25), 2799-2817 (2010).
31. Damier P, Kastner A, Agid Y, Hirsch EC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 46(5), 1262-1269 (1996). (Pubitemid 26159284)
32. Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol. Neurobiol. 30(1), 77-89 (2004). (Pubitemid 41271221)
33. Mallajosyula JK, Kaur D, Chinta SJ et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS ONE 3(2), e1616 (2008).
34. Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R) salsolinol, leading to apoptosis in SH-SY5Y cells. J. Neurochem. 96(2), 541-549 (2006).
35. De Zutter GS, Davis RJ. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl Acad. Sci. USA 98(11), 6168-6173 (2001). (Pubitemid 32488211)
36. Ou XM, Chen K, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl Acad. Sci. USA 103(29), 10923-10928 (2006). (Pubitemid 44148396)
37. Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billett EE. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J. Neurochem. 103(6), 2189-2199 (2007). (Pubitemid 350173561)
38. Fitzgerald JC, Ufer C, Billett EE. A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells. J. Neural Transm. 114(6), 807-810 (2007). (Pubitemid 46980489)
39. Maruyama W, Nitta A, Shamoto-Nagai M et al. N-Propargyl-1-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-B transcription factor. Neurochem. Int. 44(6), 393-400 (2004). (Pubitemid 37548404)
40. Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int. Rev. Neurobiol. 100, 85-106 (2011).
41. Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J. Neural Transm. 119(4), 405-414 (2012).
42. Maruyama W, Naoi M. Induction of glial cell-line-derived and brain-derived neurotrophic factors by rasagiline and deprenyl: a way to a disease-modifying therapy? J. Neural Transm. 120, 83-89 (2013).
43. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B. J. Neurochem. 45(4), 1049-1054 (1985). (Pubitemid 16258148)
44. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116(3), 313-317 (1985). (Pubitemid 16191823)
45. Kupsch A, Sautter J, Gotz ME et al. Monoamine oxidase-inhibition and MPTPinduced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 108(8-9), 985-1009 (2001). (Pubitemid 32802096)
46. Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J. Neurocytol. 32(4), 329-343 (2003). (Pubitemid 38197813)
47. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 187(2), 455-459 (2004). (Pubitemid 38610291)
48. Zhang X, Zuo DM, Davis BA, Boulton AA, Yu PH. Immunohistochemical evidence of neuroprotection by R-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals. J. Neurosci. Res. 43(4), 482-489 (1996).
49. Fowler CJ, Tipton KF. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J. Neurochem. 38(3), 733-736 (1982). (Pubitemid 12120610)
50. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 18(5), 163-171 (1992).
51. Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31(2), 394-400 (1992).
52. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60(2), 387-393 (1998). (Pubitemid 28282679)
53. Speiser Z, Mayk A, Litinetsky L et al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J. Neural Transm. 114(5), 595-605 (2007). (Pubitemid 46664052)
54. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 210(2), 421-427 (2008).
55. Eliash S, Dror V, Cohen S, Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 1256, 138-148 (2009).
56. Maruyama W, Abe T, Tohgi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann. Neurol. 40(1), 119-122 (1996). (Pubitemid 26250152)
57. Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS. (R)salsolinol N-methyltransferase activity increases in Parkinsonian lymphocytes. Ann. Neurol. 43(2), 212-216 (1998). (Pubitemid 28110123)
58. Naoi M, Maruyama W, Dostert P et al. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 709(2), 285-295 (1996).
59. Akao Y, Nakagawa Y, Maruyama W, Takahashi T, Naoi M. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3. Neurosci. Lett. 267(3), 153-156 (1999). (Pubitemid 29254084)
60. Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N- methylpropargylamine. J. Neural Transm. 108(1), 11-24 (2001). (Pubitemid 32692610)
61. Maruyama W, Naoi M, Kasamatsu T et al. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 69(1), 322-329 (1997). (Pubitemid 27274188)
62. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78(4), 727-735 (2001). (Pubitemid 32777974)
63. Akao Y, Maruyama W, Shimizu S et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J. Neurochem. 82(4), 913-923 (2002).
64. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 305(5684), 626-629 (2004). (Pubitemid 39006738)
65. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87(1), 99-163 (2007). (Pubitemid 46209992)
66. Kinnally KW, Antonsson B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis 12(5), 857-868 (2007). (Pubitemid 46653291)
67. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 10(7), 481-494 (2009).
68. Beutner G, Rück A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim. Biophys. Acta 1368(1), 7-18 (1998). (Pubitemid 28031936)
69. Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 12(5), 815-833 (2007). (Pubitemid 46653292)
70. Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim. Biophys. Acta 1813(4), 616-622 (2011).
71. Sileikyte J, Petronilli V, Zulian A et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J. Biol. Chem. 286(2), 1046-1053 (2011).
72. Tsujimoto Y, Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 7(12), 1174-1181 (2000). (Pubitemid 32042224)
73. Wadia JS, Chalmers-Redman RM, Ju WJ et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18(3), 932-947 (1998). (Pubitemid 28112916)
74. Lee CS, Lee CS, Ko HH, Song JH, Han ES. Effect of R-(-)-deprenyl and harmaline on dopamine-and peroxynitrite-induced membrane permeability transition in brain mitochondria. Neurochem. Res. 27(3), 215-224 (2002). (Pubitemid 34275681)
75. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech. Ageing Dev. 111(2-3), 189-200 (1999).
76. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116(2-3), 181-191 (2000).
77. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24(5), 675-682 (2002). (Pubitemid 35013527)
78. Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of outer membrane translocator protein (18 kDA), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J. Neural Transm. (2013) (In Press).
79. Galluzzi L, Morselli E, Kepp O, Kroemer G. Targeting post-mitochondrial effectors of apoptosis for neuroprotection. Biochim. Biophys. Acta 1787(5), 402-413 (2009).
80. Sayeed I, Parvez S, Wali B, Siemen D, Stein DG. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 1263, 165-173 (2009).
81. Martel C, Huynh le H, Garnier A, Ventura-Clapier R, Brenner C. Inhibition of the mitochondrial permeability transition for cytoprotection: direct versus indirect mechanisms. Biochem. Res. Int. 2012, 213403 (2012).
82. Soane L, Fiskum G. Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins. J. Bioenerg. Biomembr. 37(3), 179-190 (2005). (Pubitemid 41420473)
83. Vila M, Jackson-Lewis V, Vukosavic S et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1, 2,3,6- tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98(5), 2837-2842 (2001). (Pubitemid 32209570)
84. Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 147(Suppl. 1), S287-S296 (2006). (Pubitemid 43077287)
85. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243(3), 241-247 (1993). (Pubitemid 23313289)
86. Thomas CE, Huber EW, Ohlweiler DF. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic. Biol. Med. 22(4), 733-737 (1997). (Pubitemid 27043411)
87. Kitani K, Minami C, Isobe K et al. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Dev. 123(8), 1087-1100 (2002). (Pubitemid 34603092)
88. Subramanian MV, James TJ. Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats. Cell Stress Chaperones 15(5), 743-751 (2010).
89. Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol. Pharmacol. 68(5), 1408-1414 (2005). (Pubitemid 41539996)
90. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57(1), 2-12 (2000). (Pubitemid 30033254)
91. Ou XM, Stockmeier CA, Meltzer HY et al. A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol. Psychiatry 67(9), 855-863 (2010).
92. Hara MR, Thomas B, Cascio MB et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl Acad. Sci. USA 103(10), 3887-3889 (2006). (Pubitemid 43376650)
93. Ou XM, Lu D, Johnson C et al. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16(2), 148-159 (2009).
94. Shacka JJ, Roth KA. Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr. Drug Targets. CNS Neurol. Disord. 4(1), 25-39 (2005). (Pubitemid 41408406)
95. Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins. Cell Death Differ. 13(8), 1250-1255 (2006). (Pubitemid 44057453)
96. Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltagedependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl Acad. Sci. USA 97(7), 3100-3105 (2000). (Pubitemid 30183262)
97. Malik JM, Shevtsova Z, Bahr M, Kügler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol. Ther. 11(3), 373-381 (2005). (Pubitemid 40277313)
98. Offen D, Beart PM, Cheung NS et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci. USA 95(10), 5789-5794 (1998). (Pubitemid 28224175)
99. Natsume A, Mata M, Goss J et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDAinduced degeneration. Exp. Neurol. 169(2), 231-238 (2001). (Pubitemid 32524419)
100. Cao YJ, Shibata T, Rainov NG. Liposomemediated transfer of the Bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model. Gene Ther. 9(6), 415-419 (2002). (Pubitemid 34414040)
101. Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275(5303), 1129-1132 (1997). (Pubitemid 27097312)
102. Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 71, 67-77 (2006). (Pubitemid 351412108)
103. Naoi M, Maruyama W, Inaba-Hasegawa K. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr. Top. Med. Chem. 12(20), 2177-2188 (2012).
104. Chiou SH, Ku HH, Tsai TH et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellularregulated kinase pathway. Br. J. Pharmacol. 148(5), 587-598 (2006).
105. Yi H, Maruyama W, Akao Y et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113(1), 21-32 (2006). (Pubitemid 41828953)
106. Grimsby J, Toth M, Chen K et al. Increased stress response and-phenylethylamine in MAOB-deficient mice. Nat. Genet. 17(2), 206-210 (1997).
107. Ekblom J, Oreland L, Chen K, Shih JC. Is there a 'non-MAO' macromolecular target for L-deprenyl?: studies on MAOB mutant mice. Life Sci. 63(12), PL181-PL186 (1998). (Pubitemid 29369112)
108. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275(15), 10761-10766 (2000). (Pubitemid 30212704)
109. Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl. 72, 121-131 (2007).
110. Cammarota M, Paratcha G, Bevilaqua LR et al. Cyclic AMP-responsive element binding protein in brain mitochondria. J. Neurochem. 72(6), 2272-2277 (1999). (Pubitemid 29242176)
111. Lee J, Kim CH, Simon DK et al. Mitochondrial cyclic AMP response elementbinding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280(49), 40398-40401 (2005). (Pubitemid 41780525)
112. Kulich SM, Horbinski C, Patel M, Chu CT. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 43(3), 372-383 (2007). (Pubitemid 46977632)
113. Shih JC, Chen K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 11(15), 1995-2005 (2004). (Pubitemid 38967725)
114. Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 118(7), 979-986 (2011).
115. Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 281(30), 21512-21525 (2006). (Pubitemid 44115488)
116. Duncan J, Johnson S, Ou XM. Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov. Ther. 6(3), 112-122 (2012).
117. Cao X, Li XM, Mousseau DD. Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways. Life Sci. 85(5-6), 262-268 (2009).
118. Wu JB, Shih JC. Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol. Pharmacol. 80(4), 714-723 (2011).
119. Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J. Neural Transm. 120(3), 435-444 (2013).
120. Hubalek F, Binda C, Li M et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J. Med. Chem. 47(7), 1760-1766 (2004). (Pubitemid 38380919)
121. Binda C, Hubalek F, Li M et al. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J. Med. Chem. 48(26), 8148-8154 (2005). very important for the study of biological functions of MAOs. (Pubitemid 43032523)
122. Raddatz R, Parini A, Lanier SM. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazolinebinding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J. Biol. Chem. 270(46), 27961-27968 (1995).
123. Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J. Neurochem. 96(6), 1551-1559 (2006). (Pubitemid 43351615)
124. Barac YD, Bar-Am O, Liani E et al. I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline. PLoS ONE 7(11), e47890 (2012).
125. Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C, Bompart G, Parini A. Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am. J. Physiol. Renal Physiol. 284(1), F167-F174 (2003). (Pubitemid 35471296)
126. Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU; GEPAD Study Group. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J. Geriatr. Psychiatry Neurol. 23(1), 27-34 (2010).
127. Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp. Neurobiol. 20(1), 1-17 (2011).
128. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361(1473), 1545-1564 (2006). (Pubitemid 44450210)
129. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gomez-Diaz R, Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11(7), 755-761 (2008). (Pubitemid 351896676)
130. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res. 184, 237-264 (2010).
131. Ichim G, Tauszig-Delamasure S, Mehlen P. Neurotrophins and cell death. Exp. Cell Res. 318(11), 1221-1228 (2012).
132. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3(5), 383-394 (2002). (Pubitemid 135706635)
133. Paratcha G, Ledda F. GDNF and GFR: a versatile molecular complex for developing neurons. Trends Neurosci. 31(8), 384-391 (2008).
134. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21(4), 277-288 (2001). (Pubitemid 32592504)
135. Choi-Lundberg DL, Lin Q, Chang YN et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275(5301), 838-841 (1997). (Pubitemid 27074886)
136. Oo TF, Kholodilov N, Burke RE. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J. Neurosci. 23(12), 5141-5148 (2003). (Pubitemid 36793242)
137. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res. 1052(2), 119-129 (2005). (Pubitemid 41116769)
138. Pascual A, Hidalgo-Figueroa M, Gomez-Diaz R, Lopez-Barneo J. GDNF and protection of adult central catecholaminergic neurons. J. Mol. Endocrinol. 46(3), R83-R92 (2011).
139. Burke RE, Antonelli M, Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71(2), 517-525 (1998). (Pubitemid 28480398)
140. Tomac A, Widenfalk J, Lin LF et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl Acad. Sci. USA 92(18), 8274-8278 (1995).
141. Biju K, Zhou Q, Li G et al. Macrophagemediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol. Ther. 18(8), 1536-1544 (2010).
142. Fletcher AM, Kowalczyk TH, Padegimas L, Cooper MJ, Yurek DM. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neuroscience 194, 220-226 (2011).
143. Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19(5), 922-927 (2011).
144. Kirik D, Georgievska B, Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7(2), 105-110 (2004). (Pubitemid 38129784)
145. Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9(5), 589-595 (2003). (Pubitemid 36597106)
146. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson's disease. Expert Rev. Neurother. 8(7), 1125-1139 (2008). (Pubitemid 351962079)
147. Aron L, Klein R. Repairing the Parkinsonian brain with neurotrophic factors. Trends Neurosci. 34(2), 88-100 (2011).
148. Slevin JT, Gash DM, Smith CD et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106(4), 614-620 (2007). (Pubitemid 46536457)
149. Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59(3), 459-466 (2006). (Pubitemid 43358066)
150. Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog. Neurobiol. 86(3), 186-215 (2008).
151. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19(13), 1899-1901 (2005). (Pubitemid 41598788)
152. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. 70, 457-465 (2006). (Pubitemid 44622238)
153. Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. NY Acad. Sci. 1122, 155-168 (2007). (Pubitemid 350249546)
154. Mizuta I, Ohta M, Ohta K et al. Selegiline and desmethylselegiline
155. Tang YP, Ma YL, Chao CC, Chen KY, Lee EH. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. 53(5), 593-604 (1998). (Pubitemid 28380800)
156. Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTPinduced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res. 32(10), 1694-1699 (2007). (Pubitemid 47428857)
157. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25(1), 35-44 (2007). (Pubitemid 44765215)
158. Parain K, Murer MG, Yan Q et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 10(3), 557-561 (1999). (Pubitemid 29333282)
159. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15(12), 7810-7820 (1995). (Pubitemid 26006890)
160. Gyarfas T, Knuuttila J, Lindholm P, Rantamaki T, Castren E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-Parkinsonian drug therapy in vivo. Cell. Mol. Neurobiol. 30(3), 361-368 (2010).
161. Kontkanen O, Castren E. Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res. 829(1-2), 190-192 (1999). (Pubitemid 29251700)
162. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64(6), 527-532 (2008).
163. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 455(7215), 894-902 (2008).
164. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 1211, 37-43 (2008).
165. Drzyzga LR, Marcinowska A, Obuchowicz E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res. Bull. 79(5), 248-257 (2009).
166. Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem. Res. 34(3), 536-541 (2009).
167. Eliash S, Dror V, Cohen S, Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 1256, 138-148 (2009).
168. Tazik S, Johnson S, Lu D et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox. Res. 15(3), 284-290 (2009).
169. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22(8), 3251-3261 (2002). (Pubitemid 35379212)
170. Westlund KN, Denney RM, Rose RM, Abell CW. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25(2), 439-456 (1988).
171. Riederer P, Konradi C, Hebenstreit G, Youdim MB. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol. Scand. Suppl. 126, 41-45 (1989). (Pubitemid 20022075)
172. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22, 197-217 (1999). (Pubitemid 29144886)
173. Wang J, Edmondson DE. Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Biochemistry 50(13), 2499-2505 (2011).
174. Bresjanac M, Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFR?1 as well as GDNF in vivo. Exp. Neurol. 164(1), 53-59 (2000). (Pubitemid 30490722)
175. Li X, Oghi KA, Zhang J et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426(6964), 247-254 (2003). (Pubitemid 37463137)
176. Kobayashi H, Kawakami K, Asashima M, Nishinakamura R. Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects. Mech. Dev. 124(4), 290-303 (2007). (Pubitemid 46400394)
177. Wellik DM, Hawkes PJ, Capecchi MR. Hox11 paralogous genes are essential for metanephric kidney induction. Genes Dev. 16(11), 1423-1432 (2002). (Pubitemid 34615094)
178. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch. Neurol. 59, 1937-1943 (2002).
179. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566 (2004).
180. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in Levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch. Neurol. 62, 241-248 (2005).
181. Olanow CW, Rascol O, Hauser R et al.; ADAGIO Study Investigators. A doubleblind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361(13), 1268-1278 (2009).
182. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321, 1364-1371 (1989).
183. Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329(7466), 593 (2004).
184. Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr. Opin. Neurol. 20(4), 477-483 (2007). (Pubitemid 47051997)
185. Melega WP, Cho AK, Schmitz D, Kuczenski R, Segal DS. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J. Pharmacol. Exp. Ther. 288(2), 752-758 (1999). (Pubitemid 29119691)
186. Stephans S, Yamamoto B. Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 72(3), 593-600 (1996). (Pubitemid 26124688)
187. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355(3), 169-172 (2004). (Pubitemid 38368730)
188. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 103(2), 500-508 (2007). (Pubitemid 47498024)
189. Shoulson I. An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Eur. Neurol. 32(Suppl. 1), 46-53 (1992).
190. Vanacore N. What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease? Neuroepidemiology 35(3), 213 (2010).
191. Korczyn AD, Vakhapova V. Delayed start, rapid solution? Neuroepidemiology 35(3), 214 (2010).
192. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74(14), 1143-1148 (2010).
193. Booij J, Berendse HW. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. J. Neurol. Sci. 310(1-2), 40-43 (2011).